§ 01 · Antibacterial The end of bacterial resistance.
Patented methylglyoxal disrupts the bacterial cell wall through a multi-site mechanism pathogens cannot route around. No evolutionary resistance observed across two decades.
§ 01 · Clinical-stage pharmaceutical platform Est. 2023
The end of bacterial
resistance.
Logix Biosciences develops a patented class of structurally disruptive antimicrobials, engineered to defeat resistant bacteria, act as an effective antiviral, and drive angiogenic tissue repair.
20+ yrs
No observed evolutionary resistance
2
Parallel patented assets, botanical + synthetic
3
Expedited FDA pathways in play
WHO list
Multi-drug-resistant target pathogens
§ 02 · One engine, three fronts
One composition.
Three therapeutic fronts.
A single patented engine, methylglyoxal, expressed across three modes of action. Not a pipeline of unrelated molecules: one structurally disruptive composition, three ways to deploy it.
§ 01 · Antibacterial 
§ 02 · Antiviral An effective antiviral.
The same composition acts against enveloped respiratory viruses at the point of entry, neutralizing them before infection takes hold.
§ 03 · Angiogenic An effective angiogenic.
Beyond defense, the composition promotes angiogenesis and accelerates tissue repair, driving a regenerative wound-healing pathway.
§ 03 · The platform
Not one molecule.
A patented platform.
Two independently patented compositions, one botanical and one synthetic, multiply delivery options and de-risk capital across parallel clinical pathways. Both express the same patented methylglyoxal composition.
§ Asset 01
Botanical matrixLepto242
- Composition
- Patented Medical Grade Manuka composition, a botanical matrix.
- Human use since
- 1996, a continuous documented history of human use.
- FDA pathway
- 505(b)1 botanical pathway, qualifying on prior human use.
§ Asset 02
Synthetic small moleculeLgx242
- Composition
- Synthetic methylglyoxal derivative, engineered for precision delivery.
- Designation
- QIDP under the GAIN Act: +5 years exclusivity and Fast Track.
- FDA pathway
- LPAD pathway, scaling trial burden to a resistant population.
§ 04 · Mission
To usher in the Post-Resistance Era by delivering safe, structurally disruptive antimicrobials to millions of patients globally.
§ Contact